Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
STT-5058 is a monoclonal antibody that targets the lipoprotein ApoC3 and is being developed in collaboration with Novo Nordisk.
Lead Product(s): SST-5058
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SST-5058
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2020